Biomarkers in colorectal cancer: Added value or just added expense?

Expert Review of Molecular Diagnostics

Volumn 8, Issue 3, 2008, Pages 231-233

  Saltz, Leonard B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PANITUMUMAB;

CANCER PATIENT; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENOTYPE; HUMAN; IMAGING AND DISPLAY; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR CELL; VIRUS ONCOGENE;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 44249091918     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.3.231     Document Type: Editorial

References (0)